HealthCor Management L.P. lowered its position in shares of Danaher Co. (NYSE:DHR) by 90.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 124,660 shares of the conglomerate’s stock after selling 1,127,300 shares during the period. HealthCor Management L.P.’s holdings in Danaher were worth $11,571,000 as of its most recent SEC filing.
A number of other large investors have also recently modified their holdings of DHR. Teachers Insurance & Annuity Association of America bought a new stake in Danaher during the fourth quarter valued at approximately $640,000. Stone Ridge Asset Management LLC bought a new stake in Danaher during the fourth quarter valued at approximately $470,000. Kendall Capital Management bought a new stake in Danaher during the fourth quarter valued at approximately $368,000. Guggenheim Capital LLC lifted its position in Danaher by 0.9% during the fourth quarter. Guggenheim Capital LLC now owns 880,069 shares of the conglomerate’s stock valued at $81,686,000 after purchasing an additional 7,641 shares during the last quarter. Finally, QS Investors LLC lifted its position in Danaher by 3.0% during the fourth quarter. QS Investors LLC now owns 28,849 shares of the conglomerate’s stock valued at $2,678,000 after purchasing an additional 851 shares during the last quarter. 77.83% of the stock is owned by institutional investors.
In related news, SVP Angela S. Lalor sold 42,988 shares of the company’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $102.29, for a total transaction of $4,397,242.52. Following the completion of the sale, the senior vice president now directly owns 82,008 shares in the company, valued at approximately $8,388,598.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP William K. Daniel sold 131,066 shares of the company’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $102.05, for a total transaction of $13,375,285.30. Following the sale, the executive vice president now owns 270,523 shares of the company’s stock, valued at $27,606,872.15. The disclosure for this sale can be found here. Insiders have sold a total of 313,260 shares of company stock valued at $31,657,786 over the last quarter. 12.20% of the stock is currently owned by company insiders.
Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $1.19 EPS for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.03. Danaher had a net margin of 13.60% and a return on equity of 11.36%. The company had revenue of $5.09 billion during the quarter, compared to analyst estimates of $4.97 billion. During the same period in the prior year, the business posted $1.05 EPS. The firm’s revenue was up 10.9% compared to the same quarter last year. equities analysts anticipate that Danaher Co. will post 4.37 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, April 27th. Investors of record on Thursday, March 29th will be issued a dividend of $0.16 per share. This is a positive change from Danaher’s previous quarterly dividend of $0.14. This represents a $0.64 dividend on an annualized basis and a yield of 0.62%. The ex-dividend date of this dividend is Wednesday, March 28th. Danaher’s dividend payout ratio is currently 15.86%.
Several equities research analysts have issued reports on the stock. Credit Suisse Group lifted their target price on shares of Danaher from $99.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. Stifel Nicolaus lifted their target price on shares of Danaher from $110.00 to $115.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Zacks Investment Research lowered shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, December 19th. Robert W. Baird reiterated a “buy” rating on shares of Danaher in a research report on Friday, January 12th. Finally, UBS Group started coverage on shares of Danaher in a research report on Monday, January 22nd. They set a “buy” rating and a $99.97 target price for the company. One research analyst has rated the stock with a sell rating, six have issued a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $101.23.
COPYRIGHT VIOLATION WARNING: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/03/12/danaher-co-dhr-position-reduced-by-healthcor-management-l-p.html.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.